Lipid nanoparticles for cyclosporine a administration: Development, characterization, and in vitro evaluation of their immunosuppression activity
Resumen: Cyclosporine A (CsA) is an immunosuppressant commonly used in transplantation for prevention of organ rejection as well as in the treatment of several autoimmune disorders. Although commercial formulations are available, they have some stability, bioavailability, and toxicity related problems. Some of these issues are associated with the drug or excipients and others with the dosage forms. With the aim of overcoming these drawbacks, lipid nanoparticles (LN) have been proposed as an alternative, since excipients are biocompatible and also a large amount of surfactants and organic solvents can be avoided. CsA was successfully incorporated into LN using the method of hot homogenization followed by ultrasonication. Three different formulations were optimized for CsA oral administration, using different surfactants: Tween® 80, phosphatidylcholine, taurocholate and Pluronic® F127 (either alone or mixtures). Freshly prepared Precirol nanoparticles showed mean sizes with a narrow size distribution ranging from 121 to 202 nm, and after freeze-drying were between 163 and 270 nm, depending on the stabilizer used. Surface charge was negative in all LN developed. High CsA entrapment efficiency of approximately 100% was achieved. Transmission electron microscopy was used to study the morphology of the optimized LN. Also, the crystallinity of the nanoparticles was studied by X-ray powder diffraction and differential scanning calorimetry. The presence of the drug in LN surfaces was confirmed by X-ray photoelectron spectroscopy. The CsA LN developed preserved their physicochemical properties for 3 months when stored at 4°C. Moreover, when the stabilizer system was composed of two surfactants, the LN formulations were also stable at room temperature. Finally, the new CsA formulations showed in vitro dose-dependent immunosuppressive effects caused by the inhibition of IL-2 levels secreted from stimulated Jurkat cells. The findings obtained in this paper suggest that new lipid nanosystems are a good alternative to produce physicochemically stable CsA formulations for oral administration.
Idioma: Inglés
DOI: 10.2147/IJN.S90849
Año: 2015
Publicado en: International Journal of Nanomedicine 10 (2015), 6541-6553
ISSN: 1176-9114

Factor impacto JCR: 4.32 (2015)
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 40 / 255 = 0.157 (2015) - Q1 - T1
Categ. JCR: NANOSCIENCE & NANOTECHNOLOGY rank: 26 / 83 = 0.313 (2015) - Q2 - T1

Factor impacto SCIMAGO: 1.323 - Bioengineering (Q1) - Biomaterials (Q1) - Biophysics (Q1) - Organic Chemistry (Q1) - Medicine (miscellaneous) (Q1) - Nanoscience and Nanotechnology (Q1) - Drug Discovery (Q1)

Tipo y forma: Article (Published version)
Área (Departamento): Área Ingeniería Química (Dpto. Ing.Quím.Tecnol.Med.Amb.)

Creative Commons You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes.


Exportado de SIDERAL (2021-01-21-10:45:53)

Este artículo se encuentra en las siguientes colecciones:
Articles



 Record created 2015-12-15, last modified 2021-01-21


Versión publicada:
 PDF
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)